13052-99-8

Usage

Uses

Used in Pharmaceutical Industry:
5,6,7,8-Tetrahydronaphthalen-2-ylacetic acid is used as an intermediate in the synthesis of various pharmaceuticals for its anti-inflammatory and analgesic properties. It plays a crucial role in the development of non-steroidal anti-inflammatory drugs (NSAIDs) and other medications.
Used in Agricultural Industry:
In the agricultural sector, 5,6,7,8-Tetrahydronaphthalen-2-ylacetic acid is utilized as an intermediate in the production of agrochemicals, contributing to the development of effective and innovative solutions for crop protection and enhancement.
Used in Fragrance Industry:
5,6,7,8-Tetrahydronaphthalen-2-ylacetic acid is used as a component in the production of fragrances and flavoring agents, adding unique scents and enhancing the sensory experience of various products in this industry.

InChI:InChI=1/C12H14O2/c13-12(14)8-9-5-6-10-3-1-2-4-11(10)7-9/h5-7H,1-4,8H2,(H,13,14)/p-1

Upstream product

• 3160-18-7 <6-(1,2,3,4-tetrahydronaphthalenyl)>acetonitrile 
• 774-55-0 6-Acetyl-1,2,3,4-tetrahydronaphthalene 
• 5452-58-4 1-morpholin-4-yl-2-(5,6,7,8-tetrahydronaphthalen-2-yl)-ethanethione 
• 17450-63-4 6-chloromethyl-1,2,3,4-tetrahydronaphthalene 

Downstream Products

• 384823-01-2 N-[2-(3,4-dimethoxyphenyl)ethyl]-2-(5,6,7,8-tetrahydronaphthalen-2-yl)acetamide 
• 13053-00-4 (5,6,7,8-tetrahydro-[2]naphthyl)-acetic acid amide 

Relevant academic research and scientific papers

Selective κ-opioid agonists: Synthesis and structure-activity relationships of piperidines incorporating an oxo-containing acyl group

This study describes the synthesis and the structure-activity relationships (SARs) of the (S)-(-)-enantiomers of a novel class of 2- (aminomethyl)piperidine derivatives, using κ-opioid binding affinity and antinociceptive potency as the indices of biological activity. Compounds incorporating the 1-tetralon-6-ylacetyl residue (30 and 34-45) demonstrated an in vivo antinociceptive activity greater than predicted on the basis of their κ-binding affinities. In particular, (2S)-2-[(dimethylamino)methyl]- 1-[(5,6,7,8-tetrahydro-5-oxo-2-naphthyl)acetyl]piperidine (34) was found to have a potency similar to spiradoline in animal models of antinociception after subcutaneous administration, with ED50s of 0.47 and 0.73 μmol/kg in the mouse and in the rat abdominal constriction tests, respectively. Further in vivo studies in mice and/or rats revealed that compound 34, compared to other selective κ-agonists, has a reduced propensity to cause a number of κ-related side effects, including locomotor impairment/sedation and diuresis, at antinociceptive doses. For example, it has an ED50 of 26.5 μmol/kg sc in the rat rotarod model, exhibiting a ratio of locomotor impairment/sedation vs analgesia of 36. Possible reasons for this differential activity and its clinical consequence are discussed.

ARENES FROM ALKANES OR CYCLOALKANES THROUGH DEHYDRATION OR REARRANGEMENT WITH PYRIDINIUM CHLORIDE

The preparations of various kinds of arylacetic acids both from the precursors and from the synthetic equivalents of (2-oxocyclohexenyl)acetic acids are reviewed.Particular attention is paid to the methods by which these intermediates can be obtained since the usefulness of the reaction is obviously bound to substrate availability.Further developments in the field of aromatic hydrocarbons and heterocyclic compounds are illustrated and a model for the reaction is proposed.In addition to the data already published in scientific journals and in the patent literature, several unpublished data are reported.